9 December 2019 in European Journal of Ophthalmology
Purpose: To evaluate visual and anatomic outcomes following pars plana vitrectomy and intravitreal or subretinal tissue plasminogen activator for submacular hemorrhage in patients with age-related macular degeneration. Methods: This was a retrospective study on patients with a minimum follow-up of 12 months undertaken at a tertiary referral center. Data collected include demographic details, visual and optical coherence tomography changes, surgical details, and complications. Surgical results were compared with patients who were age and lesion size matched and treated with anti-vascular endothelial growth factor injections alone. Results: There were 36 patients in surgical and 18 patients in control group. Patients in surgical arm had pars plana vitrectomy, intravitreal tissue plasminogen activator with air 24 (67%), 6 (16%) with C3F8 gas, 1 (3%) with SF6 gas, 4 (11%) subretinal tissue plasminogen activator with air, and 1 (3%) with C2F6 as post-operative tamponade. Mean LogMAR in tissue plasminogen activator group at baseline was 1.56, and it was improved at all time points 1.06 at 1 month (p < 0.05), 0.91 at 6 months (p < 0.05), and 1.07 at 1 year (p < 0.05). Mean best corrected visual acuity in control group at baseline was 1.22LogMAR with no significant improvement at any time points: 1 month (1.27), 6 months (1.35), and 12 months (1.36). Complications included retinal detachment 5%, vitreous hemorrhage 7.5%, and cataract 19%. Conclusion: Pars plana vitrectomy with intravitreal (or subretinal) tissue plasminogen activator and pneumatic displacement can offer better outcome in comparison to anti-vascular endothelial growth factor alone in patients with submacular hemorrhage secondary to age-related macular degeneration.
2 February 2017 in British Journal of Healthcare Management
Background: Cataract formation is the most frequent complication associated with pars plana vitrectomy (PPV). A growing trend has emerged for surgeons to perform combined phacovitrectomy rather than a two-step approach, even in the absence of cataract. We performed a financial analysis of combined phacovitrectomy for epiretinal membrane (ERM). Methods: Patients who underwent phacovitrectomy for ERM over a three-year period were included in the study. Operating time and cost of theatre time per minute was assessed. Univariate sensitivity analysis was performed to examine the sensitivity of our findings to changes in case duration. Results: Combined phacovitrectomy was performed on 55 eyes. Theatre cost per minute was £14.91 (in addition to £197.49 surgical pack prices). The mean operating time for phacovitrectomy was 48 minutes (range 23–77 minutes) and mean theatre cost was £909 (range 540-1346). The average income for the hospital per combined phacovitrectomy was £914. The conclusion that combined phacovitrectomy represented the more lean approach was robust in our sensitivity analysis. Conclusion: Our findings suggest that phacovitrectomy costs less to healthcare commissioners, yet still leads to a higher income for the hospital due to its higher tariff. Combined phacovitrectomy is the lean approach compared to two-step surgery and should be recommended for all phakic patients with ERM.
11 June 2015 in International Journal of Surgery